title: New approaches tackle rising pancreatic cancer rates.
authors.forename: Vicki
authors.initials: V
authors.lastname: Brower
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D019013:CD40 Antigens / Q000187:drug effects*; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000276:immunology / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D015994:Incidence; D000074324:Ipilimumab; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology / Q000473:pathology; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D019013:CD40 Antigens; D019496:Cancer Vaccines; C000593794:GVAX vaccine; D000074324:Ipilimumab; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D003520:Cyclophosphamide